Physician profile
Stephen J Incavo
NPI 1316989478
$4,292,047.53
in general payments reported to CMS, 2019-2025
18 companies · $209K in 2025
The $209K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467K · 2020: $475K · 2021: $595K · 2022: $1.5M · 2023: $765K · 2024: $274K · 2025: $209K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.1M · Acquisitions: $64K · Consulting Fee: $47K · Travel and Lodging: $12K · Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,122,693.67 |
| Acquisitions | $63,835.53 |
| Consulting Fee | $47,105.00 |
| Travel and Lodging | $12,152.91 |
| Food and Beverage | $1,160.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,991,146.26 | 2019-2025 | Persona, Rotating Hinge |
| Microport Orthopedics INC | $1,001,684.96 | 2019-2025 | Mpo Medial Pivot Knee |
| Smith+Nephew, INC. | $904,317.24 | 2019-2025 | Redapt, Engage Partial Knee System |
| Osteoremedies, LLC | $393,455.94 | 2019-2025 | Remedy Spacer, Remedy Spacer |
| Heron Therapeutics, INC. | $334.83 | 2021 | |
| Engage Uni, LLC | $212.90 | 2020-2021 | |
| Davol INC. | $145.21 | 2021 | |
| Stryker Corporation | $139.91 | 2019 | |
| Medacta USA, INC. | $135.12 | 2023 | Gmk Sphere |
| Amgen INC. | $121.84 | 2023 | Evenity |
| Shalby Advanced Technologies, INC. | $116.65 | 2024 | |
| Sanofi-Aventis U.S. LLC | $63.41 | 2019 | |
| Depuy Synthes Sales INC. | $57.34 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $39.96 | 2024 | |
| Bioventus LLC | $24.95 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $21.39 | 2023 | Iovera, Zilretta, Exparel |
| Pacira Therapeutics, INC. | $18.32 | 2021 | |
| Radius Health, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$765,182.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Incavo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.